Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Clesrovimab-cfor demonstrates a clear clinical advantage with significant improvement in primary outcomes, particularly in reducing RSV-associated medically attended lower respiratory infections and hospitalizations compared to placebo in Trial 004. The reported efficacy rates of 60.4% and 84.2% respectively, with high statistical significance (P < 0.001), support this rating.
Cost effectiveness
The reported ICER of $104,543 per QALY gained indicates low cost-effectiveness, as it exceeds common thresholds. While the analysis provides some insights into resource use, the high ICER suggests that the cost may not justify the benefits, warranting a B++ rating.
Quality of life
There is no direct measurement of HRQoL in the clinical trials or supporting documents. While the absence of caregiver burden measures limits the assessment, the modeled analysis suggests potential indirect benefits through reduced healthcare encounters. However, the lack of direct HRQoL data leads to a rating of B+.
Supporting Domains
Safety and Adverse Effects
Clesrovimab-cfor has a very good safety profile, with adverse events reported at similar rates to placebo in Trial 004. Most adverse events were mild to moderate, and serious adverse events were infrequent, supporting a rating of A+.
Comparator Selection
The use of placebo in Trial 004 and palivizumab in Trial 007 raises concerns about the relevance of comparators to current standard-of-care practices. While palivizumab is a recognized comparator for high-risk infants, the lack of multiple active comparators limits the robustness of the evidence.
Patient Population and Subgroups
The trial population is broadly representative, including infants of varying gestational ages and geographic locations. Subgroup analyses provide additional insights into efficacy across different demographics, supporting a rating of A+.
Care Pathway Integration
Clesrovimab-cfor can be integrated into existing healthcare pathways with minor adjustments. The administration requires healthcare provider involvement but does not necessitate significant changes to current practices, justifying an A rating.
Resource Use and Cost Implications
The economic analysis indicates a notable cost burden with the potential for high resource use, particularly in the context of the reported ICER. While some cost-saving implications are noted, the overall financial impact raises concerns, leading to a B+ rating.
Evidence Quality and Robustness
The evidence base is anchored in a well-conducted phase 2b/3 RCT with high certainty ratings for key outcomes. However, the reliance on a single trial and the absence of real-world effectiveness data introduce some limitations, justifying an A rating.
Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness and safety of clesrovimab-cfor, particularly in the absence of real-world data. While some sensitivity analyses are provided, the overall uncertainty regarding broader impacts leads to a B++ rating.
